報價延遲最少15分鐘:2025/11/15 03:03 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.86/1.05
|
|
企業價值
10.30B
|
| 資產負債 |
|
每股賬面淨值
18.15
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
4.79B
|
|
每股收益
11.21
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 03:03 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
